BE626279A - - Google Patents
Info
- Publication number
- BE626279A BE626279A BE626279DA BE626279A BE 626279 A BE626279 A BE 626279A BE 626279D A BE626279D A BE 626279DA BE 626279 A BE626279 A BE 626279A
- Authority
- BE
- Belgium
- Prior art keywords
- chloro
- diethyl
- oxide
- acid addition
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 8
- 230000001225 therapeutic Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 4
- 206010022437 Insomnia Diseases 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000240 adjuvant Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 241000214474 Doa Species 0.000 claims 1
- 241001106462 Ulmus Species 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229920001098 polystyrene-block-poly(ethylene/propylene) Polymers 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 229960001375 Lactose Drugs 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- -1 hydrochloric Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229940024545 Aluminum Hydroxide Drugs 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- RMBLRPRCSHCTGV-UHFFFAOYSA-N ClC=1C=CC2=C(C=[N+](CC=N2)[O-])C=1 Chemical compound ClC=1C=CC2=C(C=[N+](CC=N2)[O-])C=1 RMBLRPRCSHCTGV-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- OEGHKMSYOJOVNJ-UHFFFAOYSA-N N1=CC[N+](=CC2=C1C=CC=C2)[O-] Chemical compound N1=CC[N+](=CC2=C1C=CC=C2)[O-] OEGHKMSYOJOVNJ-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 210000003371 Toes Anatomy 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N al2o3 Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229960005467 algeldrate Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002996 emotional Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000000147 hypnotic Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003533 narcotic Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE626279A true BE626279A (da) |
Family
ID=197151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE626279D BE626279A (da) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE626279A (da) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0216555A2 (en) * | 1985-09-11 | 1987-04-01 | Btg International Limited | Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections |
-
0
- BE BE626279D patent/BE626279A/fr unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0216555A2 (en) * | 1985-09-11 | 1987-04-01 | Btg International Limited | Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections |
| EP0216555A3 (en) * | 1985-09-11 | 1989-11-23 | National Research Development Corporation | Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections |
| EP0452765A2 (en) * | 1985-09-11 | 1991-10-23 | Btg International Limited | Pharmaceutical composition and medical uses of dioxopiperidine derivatives, especially as immune response potentiators, antiviral and antibacterial agents |
| EP0452765A3 (en) * | 1985-09-11 | 1992-06-10 | National Research Development Corporation | Pharmaceutical composition and medical uses of dioxopiperidine derivatives, especially as immune response potentiators, antiviral and antibacterial agents |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5021456A (en) | Inhibitors of lysyl oxidase | |
| US5182297A (en) | Inhibitors of lysyl oxidase | |
| FR2466248A1 (fr) | Derives d'agents anti-inflammatoires non steroides, procede de preparation et compositions pharmaceutiques les contenant | |
| FR2658511A1 (fr) | Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant. | |
| FR2492258A1 (fr) | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole | |
| CH657359A5 (fr) | Derives d'indole, procedes pour leur preparation et composition pharmaceutique les contenant. | |
| JP2003522724A (ja) | 医薬製剤のための酸化防止剤−安定剤系 | |
| US20070203212A1 (en) | Method of treating osteoarthritis | |
| CH635328A5 (en) | Derivatives of N-(5-tetrazolyl)benzamide and pharmaceutical composition containing them | |
| KR100427003B1 (ko) | 연골 손상의 치료 방법 | |
| JPS63264421A (ja) | 高脂質血症治療剤 | |
| US20030199567A1 (en) | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | |
| FR2521134A1 (fr) | Urees et thio-urees substituees, leur procede de preparation et leur application therapeutique comme medicaments anti-atherosclereux | |
| BE626279A (da) | ||
| EP0429360B1 (fr) | Inhibition du syndrome d'abstinence | |
| AU2003255937A1 (en) | Method of treating osteoarthritis | |
| LV11818B (en) | Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide | |
| JP2772660B2 (ja) | リシルオキシダーゼの抑制剤 | |
| FR2472387A1 (fr) | Compositions pharmaceutiques pour le traitement de l'oedeme pulmonaire aigu, de certains etats de choc et de l'hyperfibrinolyse | |
| US20030166706A1 (en) | Method of treating osteoarthritis | |
| EP0575481A1 (fr) | Nouvelles compositions liquides a base de derives de la piperidine substitues en 1,4. | |
| JPH07252143A (ja) | 認知増強を誘導するベンラファキシン含有医薬組成物 | |
| BE711349A (da) | ||
| BE620468A (da) | ||
| GB2052982A (en) | Therapeutic combinations |